TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19628143

Group type: EXPERIMENTAL
Intervention: Basic screening approach
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Healthy relationship screening approach
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Bidirectional screening approach
Number of subjects: 699

Group type: COMPARATOR
Intervention: All screening approaches
Number of subjects: 699
Study: 17074625

Group type: EXPERIMENTAL
Intervention: Chronic Pain Coping Inventory (CPCI)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CPCI (65-item and 42-item versions)
Number of subjects: 250
Study: 15650310

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with grass pollen
Number of subjects: 29
Study: 12404199

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estrogen transdermal patch (ETP) 50 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dietetic advice (placebo group)
Number of subjects: 60
Study: 10090431

Group type: EXPERIMENTAL
Intervention: Timolol maleate ophthalmic gel-forming solution 0.5% (timolol gel) once daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Timolol maleate ophthalmic solution 0.5% (timolol solution) twice daily
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 202
Study: 7477219

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study: 2122715

Group type: EXPERIMENTAL
Intervention: Continuous feeding for 24 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Night feeding (from 1700 to 0900)
Number of subjects: 18
Study: 354839

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 75 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31866076

Group type: EXPERIMENTAL
Intervention: Maintenance treatment (MT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dose-reduction/discontinuation (DR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall (not specified)
Number of subjects: 103
Study: 31324734

Group type: EXPERIMENTAL
Intervention: Intensive systolic BP control (targeting <120 mm Hg)
Number of subjects: 8526

Group type: COMPARATOR
Intervention: Standard systolic BP control (targeting <140 mm Hg)
Number of subjects: 8526

Group type: EXPERIMENTAL
Intervention: Intensive systolic BP control
Number of subjects: 8526
Study: 28938961

Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis using Roche Diagnostics Elecsys proBNPII immunoassay
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis
Number of subjects: 1461
Study: 25468164

Group type: EXPERIMENTAL
Intervention: Routine follow-up
Number of subjects: 924

Group type: COMPARATOR
Intervention: Self-assessment
Number of subjects: 924
Study: 23357290

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 139

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 139
Study: 21039893

Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Teflon-coated polyester sutures
Number of subjects: 10
Study: 19790150

Group type: EXPERIMENTAL
Intervention: Everolimus with CNI reduction or discontinuation
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard-exposure CNI
Number of subjects: 145
Study: 17846353

Group type: EXPERIMENTAL
Intervention: High-dose VIT100 (0.75 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low-dose VIT100 (0.15 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 175
Study: 15475528

Group type: EXPERIMENTAL
Intervention: Intra-arterial indomethacin (to inhibit cyclooxygenase products)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra-arterial aminophylline (to block adenosine receptors)
Number of subjects: 16
Study: 11915776

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CHO-PRO
Number of subjects: 26

Group type: COMPARATOR
Intervention: P
Number of subjects: 26
Study: 10023283

Group type: EXPERIMENTAL
Intervention: Propofol 30 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 8072818

Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal capsular polysaccharide (CPS)‐protein conjugate vaccines with serotypes 6A and 23F
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal conjugate vaccine with native CPS directly linked to the carrier protein
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal conjugate vaccines with smaller CPS or a six‐carbon linker
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Conjugation of two pneumococcal CPSs
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Characteristics of the CPS and CPS‐protein linkage
Number of subjects: 118

Group type: COMPARATOR
Intervention: Licensed pneumococcal vaccine
Number of subjects: 118
Study: 3186274

Group type: EXPERIMENTAL
Intervention: 5 mg naloxone i.v.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg naloxone i.v.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29064900

Group type: EXPERIMENTAL
Intervention: Synthetic mesh in the sublay position
Number of subjects: 232

Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 232
Study: 28686535

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: PET-CT normalization after three cycles of RVD
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: PET-CT normalization before maintenance therapy
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Extramedullary disease at diagnosis
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: PET-CT normalization before maintenance
Number of subjects: 134
Study: 25483563

Group type: COMPARATOR
Intervention: PPC-5650
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 23782709

Group type: EXPERIMENTAL
Intervention: Individualized, meridian‐based syndrome differentiation and Sa‐am acupuncture treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Standard acupuncture treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: No acupuncture treatment
Number of subjects: 250
Study: 21895884

Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: entacapone 200 mg with each levodopa dose
Number of subjects: 105
Study: 19108956

Group type: EXPERIMENTAL
Intervention: Low Dose Alcohol (0.33 ml alcohol/kg body weight)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Moderate Dose Alcohol (0.75 ml/kg)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 16414441

Group type: EXPERIMENTAL
Intervention: High-volume hemodiafiltration (HDF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 22
Study: 15319613

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 719

Group type: COMPARATOR
Intervention: Mail interview followed by telephone interview
Number of subjects: 719
Study: 11763935

Group type: EXPERIMENTAL
Intervention: 0.03% triclosan mouthrinse (15 ml, twice daily for 21 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo mouthrinse (15 ml, twice daily for 21 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.03% triclosan mouthrinse
Number of subjects: 21
Study: 9487838

Group type: EXPERIMENTAL
Intervention: Sonicare
Number of subjects: 66

Group type: COMPARATOR
Intervention: Braun
Number of subjects: 66
Study: 8225695

Group type: EXPERIMENTAL
Intervention: silybin 240 mg b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3544654

Group type: EXPERIMENTAL
Intervention: Femoxetine 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29577381

Group type: EXPERIMENTAL
Intervention: Multiple fixed cameras
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Traditional audio with live US stream
Number of subjects: 36

Group type: COMPARATOR
Intervention: Instructional video
Number of subjects: 36

Group type: COMPARATOR
Intervention: No instructional video
Number of subjects: 36
Study: 26647971

Group type: EXPERIMENTAL
Intervention: THC (Δ(9)‐tetrahydrocannabinol)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25491026

Group type: EXPERIMENTAL
Intervention: MOVI-2 intervention (play-based and non-competitive activities)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 712
Study: 21840138

Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Modafinil (200mg and 400mg combined)
Number of subjects: 210
Study: 20022600

Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 100
Study: 18695158

Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 37.5/150 mg daily
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 75/300 mg daily
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 150/600 mg daily
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 15374865

Group type: EXPERIMENTAL
Intervention: Hotelling's T2 statistic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Univariate procedure
Number of subjects: 0
Study: 14583179

Group type: COMPARATOR
Intervention: Serum and urine NO levels in microalbuminurics
Number of subjects: 98

Group type: COMPARATOR
Intervention: Serum and urine NO levels in normoalbuminurics
Number of subjects: 98

Group type: COMPARATOR
Intervention: Hyperfiltration in normoalbuminurics
Number of subjects: 98

Group type: COMPARATOR
Intervention: Hyperfiltration in microalbuminurics
Number of subjects: 98

Group type: COMPARATOR
Intervention: Plasma MDA levels in microalbuminurics
Number of subjects: 98

Group type: COMPARATOR
Intervention: Plasma MDA levels in normoalbuminurics
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Serum glucose correlation in microalbuminurics
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation in normoalbuminurics
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation in microalbuminurics
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: HbA1c levels correlation in normoalbuminurics
Number of subjects: 98
Study: 11463592

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support ventilation (PSV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trials (SB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historical control patients (uncontrolled clinical practice)
Number of subjects: 52
Study: 9753211

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/Kg intravenously
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg/Kg intravenously
Number of subjects: 168

Group type: COMPARATOR
Intervention: 0.07 mg/Kg diazepam orally
Number of subjects: 168

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 168
Study: 8184348

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Debridement surgery
Number of subjects: 105
Study: 3110315

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g preoperative oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pivampicillin (high-dose short-term broad spectrum penicillin)
Number of subjects: 0
Study: 31028900

Group type: EXPERIMENTAL
Intervention: Upper-limb robotic-assisted therapy (RAT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 45
Study: 29166223

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (10 sessions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 24288364

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus telmisartan (80 mg/d)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus irbesartan (300 mg/d)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus olmesartan (20 mg/d)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (telmisartan, irbesartan, olmesartan)
Number of subjects: 151
Study: 23454151

Group type: EXPERIMENTAL
Intervention: Ureteroscopy in neurogenic bladder patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ureteroscopy in controls
Number of subjects: 20
Study: 21399485

Group type: EXPERIMENTAL
Intervention: Donepezil (5 to 10 mg/d) for 6 months
Number of subjects: 529
Study: 18685810

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Aspirin 100 mg every other day
Number of subjects: 49
Study: 16520442

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15486837

Group type: EXPERIMENTAL
Intervention: artesunate plus mefloquine
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 330

Group type: COMPARATOR
Intervention: chloroquine plus sulfadoxine-pyrimethamine
Number of subjects: 330
Study: 10960017

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Enamel matrix proteins combined with bovine porous bone mineral (EMP/BPBM)
Number of subjects: 21
Study: 9181906

Group type: EXPERIMENTAL
Intervention: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nephrectomy alone (Control)
Number of subjects: 20
Study: 8436025

Group type: EXPERIMENTAL
Intervention: Attributional intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Attention training program
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 101
Study: 31965842

Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 132
Study: 28562458

Group type: EXPERIMENTAL
Intervention: Flipped model (FC)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Traditional model (TC)
Number of subjects: 318
Study: 24906541

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 7832

Group type: EXPERIMENTAL
Intervention: Abnormal fasting glucose (AFG) plus high triglycerides (TGs)
Number of subjects: 7832

Group type: EXPERIMENTAL
Intervention: Abnormal fasting glucose (AFG) alone
Number of subjects: 7832

Group type: EXPERIMENTAL
Intervention: High triglycerides (TGs) alone
Number of subjects: 7832

Group type: COMPARATOR
Intervention: Normal fasting glucose plus normal TGs (reference group)
Number of subjects: 7832
Study: 22730929

Group type: EXPERIMENTAL
Intervention: LPV/r+RAL
Number of subjects: 206

Group type: COMPARATOR
Intervention: LPV/r+TDF/FTC
Number of subjects: 206
Study: 21716146

Group type: COMPARATOR
Intervention: Gemcitabine 1200 mg/m on days 1 and 8 every 21 days (Arm A)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Erlotinib 150 mg daily (Arm B)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 every 21 days and erlotinib 100 mg daily (Arm C)
Number of subjects: 146
Study: 18294489

Group type: COMPARATOR
Intervention: NYHA functional class I
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: NYHA functional class II
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: NYHA functional class III
Number of subjects: 14703
Study: 17313002

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Hegu (LI 4) and intravenous drip of oxytocin
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intravenous drip of oxytocin
Number of subjects: 276
Study: 14641801

Group type: EXPERIMENTAL
Intervention: PPARD +294C allele
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Homozygous C-allele carriers
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Gene-gene interaction involving PPARD polymorphism and PPAR alpha L162V polymorphism
Number of subjects: 1740
Study: 11053823

Group type: EXPERIMENTAL
Intervention: Median sternotomy with CPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Median sternotomy and off-pump
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minithoracotomy with CPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minithoracotomy and off-pump
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 40
Study: 9365351

Group type: EXPERIMENTAL
Intervention: Subjects without disc herniation (33 subjects)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subjects with disc herniation (27 subjects)
Number of subjects: 60
Study: 1585959

Group type: EXPERIMENTAL
Intervention: Innovative weight gain prevention intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nonspecific treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 158
Study: 3898891

Group type: EXPERIMENTAL
Intervention: Phenol chemical sympathectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo bupivacaine injection
Number of subjects: 41
Study: 30458732

Group type: EXPERIMENTAL
Intervention: First-line treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition, followed on progression by fulvestrant
Number of subjects: 1050

Group type: COMPARATOR
Intervention: First-line treatment with a non-steroidal aromatase inhibitor, followed on progression by fulvestrant combined with CDK4/6 inhibition
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Overall survival, safety, quality of life, and cost-effectiveness
Number of subjects: 1050
Study: 26875070

Group type: EXPERIMENTAL
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 556
Study: 25277144

Group type: EXPERIMENTAL
Intervention: Selexipag (400-1,800 µg, twice daily for 3 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 16
Study: 22402145

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to 7.5 mg/day in 7 weeks
Number of subjects: 610
Study: 20802246

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4662
Study: 17297026

Group type: COMPARATOR
Intervention: Primaquine 210 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primaquine 315 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primaquine 420 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight-based primaquine dose
Number of subjects: 0
Study: 15287405

Group type: EXPERIMENTAL
Intervention: Thigh tourniquet
Number of subjects: 32

Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 32
Study: 11685933

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study: 9158465

Group type: EXPERIMENTAL
Intervention: Adrenaline injection alone
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heat probe treatment
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Adrenaline injection alone (subgroup with spurting haemorrhage)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heat probe treatment (subgroup with spurting haemorrhage)
Number of subjects: 276
Study: 8260854

Group type: EXPERIMENTAL
Intervention: Topical steroid (fluticasone propionate [FP] 100 micrograms twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3630936

Group type: EXPERIMENTAL
Intervention: Eating test (high-carbohydrate meal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control test (water)
Number of subjects: 16
Study: 30728488

Group type: EXPERIMENTAL
Intervention: ranibizumab + PRP
Number of subjects: 49

Group type: COMPARATOR
Intervention: ranibizumab only
Number of subjects: 49
Study: 29114088

Group type: EXPERIMENTAL
Intervention: Primary Onyx embolization
Number of subjects: 61
Study: 27690510

Group type: EXPERIMENTAL
Intervention: Solution hints available
Number of subjects: 476

Group type: COMPARATOR
Intervention: No solution hints available
Number of subjects: 476
Study: 25133962

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 22287677

Group type: EXPERIMENTAL
Intervention: Glucosamine and glucosamine‐chondroitin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chicken cartilage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabbit hair, skin, and bone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen and rabbit bone
Number of subjects: 0
Study: 19650913

Group type: EXPERIMENTAL
Intervention: PhysioDirect
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1875
Study: 18077302

Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) skills
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Patient speech during BAI
Number of subjects: 367